Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0194-0499, Semaglutide, and Cagrilintide in Alcohol-related Liver Disease
NCT06409130Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- May 2024
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Hormonal Peptides, Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of nn9500, cagrilintide, semaglutide in alcoholic liver disease (ALD), sponsored by Novo Nordisk. Started May 2024; status: completed.
02
Drugs
03
Conditions
alcoholic liver disease (ALD)
Beyond the preview
Go deeper on NCT06409130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06409130.